Pfizer Inc (PFE) Enterprise Value to Invested Capital (EV/IC): 1.77

Since December 31st, 2008, Pfizer Inc's enterprise value to invested capital (ev/ic) has increased from 1.34 to 1.77 at September 29th, 2023.

From 2008 to 2023 Pfizer Inc's highest enterprise value to invested capital (ev/ic) was 4.62
Pfizer Inc's lowest enterprise value to invested capital (ev/ic) during that period was 0.81
Pfizer Inc's average enterprise value to invested capital (ev/ic) from 2008 to 2023 Pfizer Inc's was 2.04

Pfizer Inc's enterprise value to invested capital (ev/ic) as of September 29th, 2023 of 1.77 was lower than its peers in the Drug Manufacturers - Major industry group of August 31st, 2023 of 243.46. From December 31st, 2008 to September 29th, 2023, Pfizer Inc's average enterprise value to invested capital (ev/ic) was 2.04 compared to an industry average of 98,260.86.

About Pfizer Inc

Pfizer, Inc. is a research-based, global biopharmaceutical company, which engages in the manufacture of vaccines and injectable biologic medicines. It operates through the following business segments: Global Innovative Pharmaceutical, Global Vaccines, Oncology and Consumer Healthcare, and Global Established Pharmaceutical. The Global Innovative Pharmaceutical segment focuses on developing, registering and commercializing novel, value creating medicines that significantly improve patients lives. The Global Vaccines, Oncology and Consumer Healthcare segment engages in the development and commercialization of vaccines and products for oncology and consumer healthcare. The Global Established Pharmaceutical segment includes the brands that have lost market exclusivity and, generally, the mature, patent-protected products that are expected to lose exclusivity through 2015 in most major markets and, to a much smaller extent, generic pharmaceuticals. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.